Insight Molecular Diagnostics Inc IMDX.OQ IMDX.O is expected to show a fall in quarterly revenue when it reports results on March 26 for the period ending December 31 2025
The Nashville Tennessee-based company is expected to report a 80.5% decrease in revenue to $290 thousand from $1.49 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Insight Molecular Diagnostics Inc is for a loss of 24 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Insight Molecular Diagnostics Inc is $9.00, about 125% above its last closing price of $4.00
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.22 | -0.21 | -0.34 | Missed | -62.1 |
Jun. 30 2025 | -0.23 | -0.23 | -0.30 | Missed | -30.4 |
Mar. 31 2025 | -0.24 | -0.24 | -0.26 | Missed | -9.9 |
Dec. 31 2024 | -0.44 | -0.43 | -1.93 | Missed | -351.6 |
Sep. 30 2024 | -0.44 | -0.44 | -0.98 | Missed | -124.8 |
Jun. 30 2024 | -0.55 | -0.56 | -0.36 | Beat | 35.6 |
Mar. 31 2024 | -0.65 | -0.67 | -1.13 | Missed | -69.1 |
Dec. 31 2023 | -1.14 | -2.12 | Missed | -86.5 |
This summary was machine generated March 24 at 20:24 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)